Duopharma Biotech Bhd.(MY:7148)
RM1.10+0.03 (+2.80%)
MY:7148
Duopharma Biotech Bhd. financials statements
RM1.10
At close:+0.03 (+2.80%)
Duopharma Biotech Bhd. (7148) Ratios
Duopharma Biotech Bhd. Ratios
MY:7148's free cash flow for Q2 2026 was RM-3.72M. For the 2026 fiscal year, MY:7148's free cash flow was decreased by RM-5.78M and operating cash flow was RM2.05M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.61 | 4.10 | 4.06 | 2.05 | 2.15 |
| Quick Ratio | 1.68 | 2.70 | 2.60 | 1.16 | 1.18 |
| Cash Ratio | 0.93 | 1.49 | 1.62 | 0.60 | 0.60 |
| Solvency Ratio | 0.19 | 0.16 | 0.15 | 0.19 | 0.18 |
| Operating Cash Flow Ratio | 0.36 | 0.46 | 0.27 | 0.27 | 0.19 |
| Short-Term Operating Cash Flow Coverage | 0.76 | 1.71 | 0.70 | 0.52 | 0.42 |
| Net Current Asset Value | RM 128.73M | RM 59.20M | RM 19.05M | RM -25.21M | RM -45.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.34 | 0.37 | 0.41 | 0.35 | 0.35 |
| Debt-to-Equity Ratio | 0.65 | 0.73 | 0.80 | 0.66 | 0.65 |
| Debt-to-Capital Ratio | 0.39 | 0.42 | 0.44 | 0.40 | 0.39 |
| Long-Term Debt-to-Capital Ratio | 0.31 | 0.40 | 0.41 | 0.31 | 0.32 |
| Financial Leverage Ratio | 1.91 | 1.94 | 1.96 | 1.86 | 1.87 |
| Debt Service Coverage Ratio | 0.96 | 1.80 | 1.36 | 0.81 | 0.96 |
| Interest Coverage Ratio | 5.92 | 3.79 | 4.44 | 10.21 | 13.78 |
| Debt to Market Cap | 0.41 | 0.43 | 0.46 | 0.28 | 0.26 |
| Interest Debt Per Share | 0.54 | 0.56 | 0.59 | 0.46 | 0.44 |
| Net Debt to EBITDA | 1.05 | 1.65 | 2.24 | 2.10 | 2.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 38.98% | 37.06% | 38.08% | 40.16% | 39.74% |
| EBIT Margin | 15.72% | 13.10% | 11.56% | 13.48% | 13.99% |
| EBITDA Margin | 20.62% | 18.68% | 17.67% | 18.75% | 19.07% |
| Operating Profit Margin | 15.72% | 12.37% | 11.48% | 13.34% | 13.89% |
| Pretax Profit Margin | 12.33% | 9.83% | 8.98% | 12.18% | 12.98% |
| Net Profit Margin | 9.39% | 7.70% | 7.47% | 10.06% | 10.28% |
| Continuous Operations Profit Margin | 9.39% | 7.70% | 7.47% | 10.06% | 10.28% |
| Net Income Per EBT | 76.12% | 78.28% | 83.21% | 82.63% | 79.15% |
| EBT Per EBIT | 78.44% | 79.51% | 78.23% | 91.33% | 93.49% |
| Return on Assets (ROA) | 6.04% | 4.55% | 3.91% | 5.74% | 5.64% |
| Return on Equity (ROE) | 11.54% | 8.83% | 7.66% | 10.70% | 10.53% |
| Return on Capital Employed (ROCE) | 12.91% | 8.39% | 6.86% | 9.71% | 9.50% |
| Return on Invested Capital (ROIC) | 8.70% | 6.31% | 5.41% | 7.03% | 6.77% |
| Return on Tangible Assets | 6.20% | 4.70% | 4.03% | 5.95% | 5.84% |
| Earnings Yield | 7.27% | 5.21% | 4.43% | 4.59% | 4.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.96 | 3.91 | 4.86 | 4.90 | 4.82 |
| Payables Turnover | 3.50 | 7.79 | 10.79 | 48.19 | 12.30 |
| Inventory Turnover | 1.94 | 2.06 | 1.80 | 1.77 | 1.73 |
| Fixed Asset Turnover | 1.68 | 1.44 | 1.21 | 1.20 | 1.18 |
| Asset Turnover | 0.64 | 0.59 | 0.52 | 0.57 | 0.55 |
| Working Capital Turnover Ratio | 1.77 | 1.54 | 1.79 | 2.57 | 2.23 |
| Cash Conversion Cycle | 176.26 | 223.56 | 244.62 | 272.80 | 256.65 |
| Days of Sales Outstanding | 92.21 | 93.27 | 75.15 | 74.47 | 75.79 |
| Days of Inventory Outstanding | 188.21 | 177.13 | 203.30 | 205.90 | 210.55 |
| Days of Payables Outstanding | 104.16 | 46.83 | 33.83 | 7.57 | 29.68 |
| Operating Cycle | 280.42 | 270.40 | 278.45 | 280.37 | 286.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.12 | 0.09 | 0.05 | 0.07 | 0.05 |
| Free Cash Flow Per Share | 0.09 | 0.05 | 0.01 | -0.00 | -0.08 |
| Dividend Paid and CapEx Coverage Ratio | 1.87 | 1.38 | 0.95 | 0.89 | 0.27 |
| Capital Expenditure Coverage Ratio | 4.21 | 2.51 | 1.16 | 0.99 | 0.38 |
| Operating Cash Flow Coverage Ratio | 0.23 | 0.16 | 0.08 | 0.16 | 0.11 |
| Operating Cash Flow to Sales Ratio | 0.12 | 0.10 | 0.06 | 0.10 | 0.07 |
| Free Cash Flow Yield | 7.15% | 4.11% | 1.01% | -0.05% | -4.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.75 | 19.20 | 22.59 | 21.79 | 23.76 |
| Price-to-Sales (P/S) Ratio | 1.29 | 1.48 | 1.69 | 2.19 | 2.44 |
| Price-to-Book (P/B) Ratio | 1.59 | 1.70 | 1.73 | 2.33 | 2.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 13.99 | 24.32 | 99.14 | -2019.54 | -21.72 |
| Price-to-Operating Cash Flow Ratio | 10.67 | 14.63 | 25.99 | 21.73 | 36.10 |
| Price-to-Earnings Growth (PEG) Ratio | 0.35 | 1.03 | -0.88 | 4.81 | 2.10 |
| Enterprise Value Multiple | 7.31 | 9.56 | 11.79 | 13.79 | 14.97 |
| Enterprise Value | 1.40B | 1.45B | 1.47B | 1.80B | 1.83B |
| EV to EBITDA | 7.31 | 9.56 | 11.79 | 13.79 | 14.97 |
| EV to Sales | 1.51 | 1.79 | 2.08 | 2.58 | 2.86 |
| EV to Free Cash Flow | 16.34 | 29.41 | 122.35 | -2381.93 | -25.42 |
| EV to Operating Cash Flow | 12.46 | 17.69 | 32.08 | 25.63 | 42.25 |
| Tangible Book Value Per Share | 0.75 | 0.69 | 0.68 | 0.64 | 0.63 |
| Shareholders’ Equity Per Share | 0.79 | 0.74 | 0.72 | 0.69 | 0.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | 0.22 | 0.17 | 0.17 | 0.21 |
| Revenue Per Share | 0.97 | 0.85 | 0.73 | 0.73 | 0.69 |
| Net Income Per Share | 0.09 | 0.07 | 0.05 | 0.07 | 0.07 |
| Tax Burden | 0.76 | 0.78 | 0.83 | 0.83 | 0.79 |
| Interest Burden | 0.78 | 0.75 | 0.78 | 0.90 | 0.93 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.24 | 0.25 | 0.27 | 0.27 | 0.26 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.29 | 1.03 | 0.87 | 0.83 | 0.52 |
Currency in MYR
